| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
TAZ[1]
|
|---|---|
| ln Vitro |
TAZ expression is increased by IBS008738 (0, 24, 48, and 72 hours), peaking at 24 hours[1]. mRNAs in C2C12 cells are enhanced by IBS008738 (10 μM; 0, 24, 72 h) in terms of IL-10 mRNAs [2].
|
| ln Vivo |
When muscles are injected with cardiotoxin, IBS008738 (3 nmol) facilitates muscle regeneration[1]. Muscle atrophy brought on by dexamethasone is prevented by IBS008738 (30 μM, 100 μL)[1]. After traumatic brain injury (TBI), IBS008738 (30 μM in 100 μL volume; intramuscular injection; immediately and day 2 after TBI) decreases TNF alpha and IL-6 expression but enhances IL-10 mRNA expression in muscles[2].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: C2C12 cells Tested Concentrations: Incubation Duration:Treated for 0, 24, 48, 72 h under differentiation conditions after 24 h under growth conditions. Experimental Results: Enhanced TAZ expression, with a peak at 24 h. RT-PCR[1] Cell Types: C2C12 cells Tested Concentrations: 10 μM Incubation Duration: 0, 24, 72 h under differentiation Experimental Results: Enhanced mRNAs of myogenic markers but not of myofusion markers. |
| Animal Protocol |
Animal/Disease Models: Sixweeks old female BALB/cByJ mice[1]
Doses: 3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS) Route of Administration: Injected into the tibialis anterior (TA) muscle of mice under anesthesia. Experimental Results: Facilitated muscle repair in Cardiotoxin-injected muscles. Animal/Disease Models: Sixweeks old female BALB/cByJ mice[1] Doses: 30 μM (100 μL) Route of Administration: Injected into the tibialis anterior (TA) and gastrocnemius (GM ) muscles on days 9, 11, and 13. Experimental Results: Prevented Dexamethasone-induced muscle atrophy. |
| References |
[1]. Yang Z, et al. Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model. Mol Cell Biol. 2014;34(9):1607-1621.
[2]. Zou R, et al. TAZ Activator Is Involved in IL-10-Mediated Muscle Responses in an Animal Model of Traumatic Brain Injury. Inflammation. 2017;40(1):100-105. |
| Molecular Formula |
C22H22N4O2
|
|---|---|
| Molecular Weight |
374.44
|
| CAS # |
385425-03-6
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C(C1N(C2=CC=C(C)C=C2)C=NC=1N=CN1CCOCC1)(C1=CC=CC=C1)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (133.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6707 mL | 13.3533 mL | 26.7065 mL | |
| 5 mM | 0.5341 mL | 2.6707 mL | 5.3413 mL | |
| 10 mM | 0.2671 mL | 1.3353 mL | 2.6707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
